ARTICLE | Company News
Roivant, Portola deal
January 6, 2017 8:34 PM UTC
Portola granted Roivant's Dermavant Sciences subsidiary exclusive, worldwide rights to develop and commercialize cerdulatinib for topical applications outside of oncology. Dermavant said it plans to d...